Published: 2019-10-23

Comparative evaluation of different cost effective ovulation induction drugs and their effect on follicular growth, endometrial thickness and pregnancy outcome

Madhumithaa Narayanan, Uruj Jahaan, Neena Gupta


Background: Ovulatory dysfunction is a common cause of female infertility, occurring in up to 20 - 30% of infertile women. The most commonly prescribed ovulation drugs are clomiphene citrate (CC), tamoxifen, aromatase inhibitors (such as letrozole) and gonadotropins. Objective of the study was to evaluate the efficacy of clomiphene citrate, letrozole and tamoxifen for ovulation induction in anovulatory infertility.

Methods: Randomized open label interventional clinical trial. Patients were randomized to 3 drug groups. After baseline investigations, they were subjected to ovulation induction and then USG monitoring of follicular growth and ovulation. The primary outcome measured was occurrence of conception. Secondary outcome was effect on endometrial thickness and ovulation rate.

Results: In the study, letrozole group showed 100% mono-follicular response. Mid cycle endometrial thickness in about 17% of cases in CC group is ≤8 mm. But all the cases in tamoxifen and letrozole group have ET >8 mm. This difference is statistically significant. The ovulation and conception rates are highest in letrozole group but the difference was not statistically significant.

Conclusions: Letrozole produces higher mid cycle endometrial thickness, 100% mono follicular development than clomiphene and tamoxifen. This difference is found to be statistically significant. Ovulation rate and conception rate is highest in letrozole group. But there is no statistically significant difference among the three drugs.


Anovulatory infertility, Clomiphene citrate, Follicular growth, Letrozole, Ovulation rate, Ovulation induction, Tamoxifen

Full Text:



Practice Committee of the American Society for Reproductive Medicine. Definitions of infertility and recurrent pregnancy loss. Fertil Steril. 2008;90:60.

Fritz, A Marc, Speroff L. Clinical gynecologic endocrinology and infertility. 8th Ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams and Wilkins; 2011.

Richard S, Legro MD, Robert G, Brzyski MD, Michael P, Diamond MD. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014;371:119-29.

Kar S. Clomiphene citrate or letrozole for ovulation induction in women with polycystic ovarian syndrome: a prospective randomized trial. Fertil Steril. 2009;92(3):849-52.

Mitwally MFM, Casper RF. Use of an AI for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril. 2001;75:305-9.

Badawg A, Aal IA, Abulalta M. Climiphene citrate or letrozole for ovulation induction in women with polycystic ovarian syndrome: A prospective randomized trial. Fertil Steril. 2009;92:849-52.

Zeinalzadeh M, Basirat Z, Esmalpour M. Efficacy of letrozole in ovulation indication compared to that of clomiphene citrate in patients with polycystic ovarian syndrome. J Reprod Med. 2010;55:36-40.

Bayar U, Tanriverdi HA, Aykut B, Ayoglu F, Ozcan O, Erdal K. Letrozole vs clomiphene citrate in patients with ovulatory infertility. Fertil Steril. 2006;85:1045-8.

Seyedoshohadaei F, Zandvakily F, Shahgeibi S. Comparison of the effectiveness of clomiphene citrate, tamoxifen and letrozole in ovulation induction in infertility due to isolated unovulation. Iran J Reprod Med. 2012;10(6):531-6.

He D, Jiang F. Meta- analysis of letrozole versus clomiphene citrate in polycystic ovary syndrome. Reprod Biomed Online. 2011;23:91-6.